Inclusion Criteria:

- 18-65 years of age at the time of study entry

- Diagnosed with Long COVID

- Individuals of child-bearing potential must have a negative serum pregnancy test at
screening and agree to on-site urine pregnancy testing at all subsequent study
visits

- A urine drug screen performed at the Screening Visit must be negative for drugs of
abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed
amphetamines and opioids/opiates.

- Those with mild to moderate depression should be clinically stable for three months,
without risk of suicidal ideation or behavior.

Exclusion Criteria:

- Breastfeeding, pregnant, or planning to become pregnant during the next six months.

- In the opinion of the Investigator, any clinically significant, uncontrolled, or
unstable medical or surgical condition that could affect the individual's ability to
participate in the study or potentially compromise their well-being while enrolled
in the study.

- In the opinion of the Investigator or based on results of the HADS, evidence of a
clinically significant psychiatric disorder, e.g., severe, unstable or poorly
controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe
alcohol use disorder; substance use disorder other than mild cannabis use disorder;
or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other
psychotic disorder.

- Currently meeting criteria for ME/CFS at the pre-screening or screening visit, or a
prior confirmed diagnosis of ME/CFS within the last 5 years. This may be determined
as part of the initial screening call or visit.

- Any anticipated need for surgery that in the opinion of the Principal Investigator
or Sub-I might confound results or interfere with the participant's ability to
comply with the protocol.

- Symptomatic and/or otherwise clinically significant cardiac disease

- Acute non-COVID systemic infection (e.g., HIV, hepatitis) or other active viral or
bacterial infection during the screening/washout period or at the Baseline visit.

- Currently receiving chronic systemic corticosteroids (>5 mg prednisone daily, or
equivalent)

- Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid,
phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on
these medications should not be screened.

- Uncontrolled sleep apnea.

- Use of chronic nucleoside analog antiviral suppression therapy within one month of
the Screening Visit or requiring on average more than one acute treatment course
every two months.

- Current use of celecoxib either alone or in combination with valacyclovir or
famciclovir

- In the opinion of the Investigator, evidence of current drug or alcohol abuse or
dependency, or history of abuse or dependence during the preceding 12 months.

- The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y
or other bypass procedure).

- Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel
movements.